Mitralign shared six-month data on its Mitralign Percutaneous Annuloplasty System (MPAS) for treatment of functional mitral regurgitation (FMR) at EuroPCR 2015 in Paris. The prospective, multi-center, single-arm study met its safety endpoint at 30 days and its performance endpoint at six months. In the clinical study, the MPAS demonstrated a statistically significant reduction in left ventricular diameter, significant reduction of both the A-P and S-L annular dimensions, and a significant improvement of the patient’s walking distance. The Mitralign Percutaneous Annuloplasty System is not approved for sale or distribution; however it is anticipated to receive CE marking in 2015.